Depressive Disorder News and Research RSS Feed - Depressive Disorder News and Research

Cognitive therapy combined with antidepressant drug effective for severe nonchronic depression

Cognitive therapy combined with antidepressant drug effective for severe nonchronic depression

The odds that a person who suffers from severe, nonchronic depression will recover are improved by as much as 30 percent if they are treated with a combination of cognitive therapy and antidepressant medicine rather than by antidepressants alone. [More]
Bipolar II disorder course mapped in Japanese patients

Bipolar II disorder course mapped in Japanese patients

The course of bipolar II disorder can follow several distinct trajectories, with a major depressive episode being the most common presenting feature, a study of Japanese patients suggests. [More]
Neuralstem doses final patient with NSI-566 stem cells in Phase II trial

Neuralstem doses final patient with NSI-566 stem cells in Phase II trial

Neuralstem, Inc. announced that the final patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). [More]
Brain stimulation effective for treating depression

Brain stimulation effective for treating depression

Brain stimulation treatments, like electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS), are often effective for the treatment of depression. Like antidepressant medications, however, they typically have a delayed onset. [More]
Self-serving bias impaired in individuals suffering from MDD

Self-serving bias impaired in individuals suffering from MDD

Neuropsychological impairment has long been established as a fundamental characteristic of depression, but a specific pattern of impairment that is widely recognized has not been summarized. [More]
NIH funds Phase II 90-subject pediatric clinical trial at UCLA

NIH funds Phase II 90-subject pediatric clinical trial at UCLA

NeuroSigma, Inc., a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, today announced that the U.S. National Institutes of Health (NIH) has awarded UCLA a grant that funds a Phase II 90-subject pediatric clinical trial at the University of California, Los Angeles focused on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with NeuroSigma's external trigeminal nerve stimulation (eTNS) System. [More]
Patients in new DSM-5 bipolar category ‘deserve attention’

Patients in new DSM-5 bipolar category ‘deserve attention’

People who fall into the DSM-5 Other Specified Bipolar and Related Disorders category carry a significant clinical burden, a study shows. [More]
Breckenridge announces launch of Duloxetine Delayed-release Capsules

Breckenridge announces launch of Duloxetine Delayed-release Capsules

Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Duloxetine Delayed-release Capsules. [More]
New guidelines aim to improve delivery of prostate cancer survivorship care

New guidelines aim to improve delivery of prostate cancer survivorship care

New American Cancer Society Prostate Cancer Survivorship Care guidelines released today outline posttreatment clinical follow-up care for the myriad of long-term and late effects an estimated 2.8 million prostate cancer survivors in the United States may face. [More]
Alkermes initiates FORWARD-3 and FORWARD-4 efficacy studies in pivotal clinical program for ALKS 5461

Alkermes initiates FORWARD-3 and FORWARD-4 efficacy studies in pivotal clinical program for ALKS 5461

Alkermes plc today announced the initiation of FORWARD-3 and FORWARD-4, two of the three planned phase 3 core efficacy studies in the pivotal clinical program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD). [More]
Predictive factors ‘raise suspicion’ for emergence of bipolar disorder

Predictive factors ‘raise suspicion’ for emergence of bipolar disorder

Researchers have identified seven factors that predict which patients initially diagnosed with depression will later meet the diagnostic criteria for bipolar disorder. [More]
Study compares effectiveness of duloxetine and fluoxetine in children with MDD

Study compares effectiveness of duloxetine and fluoxetine in children with MDD

Two studies of the anti-depressive drug duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), compared its effectiveness and safety to either fluoxetine or placebo in children and adolescents with major depressive disorder (MDD). [More]
Biomarker predicts bipolarity in depressed patients

Biomarker predicts bipolarity in depressed patients

Measuring plasma levels of brain-derived neurotrophic factor in patients with a first episode of depression could help to predict who will go on to develop bipolar disorder, research suggests. [More]
Naurex's two lead antidepressant programs achieve major milestones

Naurex's two lead antidepressant programs achieve major milestones

Naurex Inc., a privately held biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS), today announced that its two lead antidepressant programs achieved major milestones. [More]
Pernix completes sale of Pernix Manufacturing to Woodfield Pharmaceutical

Pernix completes sale of Pernix Manufacturing to Woodfield Pharmaceutical

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, today announced that it has closed on the sale of its Houston, TX-based manufacturing operations, Pernix Manufacturing, LLC ("PML") to Woodfield Pharmaceutical LLC. [More]
Intranasal ketamine spray confers rapid antidepressant effect in patients with depressive disorder

Intranasal ketamine spray confers rapid antidepressant effect in patients with depressive disorder

A research team from the Icahn School of Medicine at Mount Sinai published the first controlled evidence showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect -within 24 hours-and was well tolerated in patients with treatment-resistant major depressive disorder. [More]
Deutsche Forschungsgemeinschaft to establish 5 new Research Units

Deutsche Forschungsgemeinschaft to establish 5 new Research Units

Topics Range from Composite Structures to Personnel Decisions to Metastatic Cancer Progression / About Eleven Million Euros in Funding for Three Years [More]
NeuroSigma gets approval to market Monarch eTNS System in Australia

NeuroSigma gets approval to market Monarch eTNS System in Australia

NeuroSigma, Inc., a California-based life-sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, today announced that it has received approval from the Therapeutic Goods Administration to market its Monarch eTNS System in Australia. [More]
Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities. [More]
Forest Laboratories, Richter report positive results from cariprazine Phase IIb trial for bipolar depression

Forest Laboratories, Richter report positive results from cariprazine Phase IIb trial for bipolar depression

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced positive topline results from a Phase IIb trial evaluating the efficacy and safety of the investigational antipsychotic cariprazine in patients with bipolar depression. [More]